Short answer
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an 8-K current report with the SEC on March 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Offering priced at $81.00/share; 7.31M shares + 402K pre-funded warrants issued, with full 1.16M share overallotment exercised next day.
Dianthus Therapeutics, Inc. /DE/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Offering priced at $81.00/share; 7.31M shares + 402K pre-funded warrants issued, with full 1.16M share overallotment exercised next day
- Net proceeds ~$673.5M after underwriting discounts and offering expenses
- Pre-funded warrants priced at $80.999 (full price minus $0.001 exercise), capped at 4.99%/9.99%/19.99% beneficial ownership limits
- Five-bank syndicate led by Jefferies, TD Securities, Evercore, Stifel, and Guggenheim: broad institutional placement signal
- Closing expected March 12, 2026; raises substantial cash runway for clinical-stage biotech, likely funding Phase 2/3 programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dianthus Therapeutics, Inc. /DE/ 8-K filings
Get the next DNTH 8-K as it lands
Follow DNTH for push alerts, or ask the research agent what this filing means.